ASCO Annual Meeting 2023: Adding Durvalumab and Olaparib to Treatment Delays Growth of Ovarian Cancer
The ASCO Annual Meeting is being held June 2 to 6. A study that will be presented today explores combining immunotherapy and targeted therapy to reduce the risk of death and recurrence for people with advanced ovarian cancer.